RT Journal Article
SR Electronic
T1 Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.04.21252528
DO 10.1101/2021.03.04.21252528
A1 Daniel J Grint
A1 Kevin Wing
A1 Elizabeth Williamson
A1 Helen I McDonald
A1 Krishnan Bhaskaran
A1 David Evans
A1 Stephen JW Evans
A1 Alex J Walker
A1 George Hickman
A1 Emily Nightingale
A1 Anna Schultze
A1 Christopher T Rentsch
A1 Chris Bates
A1 Jonathan Cockburn
A1 Helen J Curtis
A1 Caroline E Morton
A1 Sebastian Bacon
A1 Simon Davy
A1 Angel YS Wong
A1 Amir Mehrkar
A1 Laurie Tomlinson
A1 Ian J Douglas
A1 Rohini Mathur
A1 Paula Blomquist
A1 Brian McKenna
A1 Peter Ingelsby
A1 Richard Croker
A1 John Parry
A1 Frank Hester
A1 Sam Harper
A1 Nicholas J DeVito
A1 Will Hulme
A1 John Tazare
A1 Ben Goldacre
A1 Liam Smeeth
A1 Rosalind M Eggo
YR 2021
UL http://medrxiv.org/content/early/2021/03/08/2021.03.04.21252528.abstract
AB The B.1.1.7 variant of concern (VOC) is increasing in prevalence across Europe. Accurate estimation of disease severity associated with this VOC is critical for pandemic planning. We found increased risk of death for VOC compared with non-VOC cases in England (HR: 1.67 (95% CI: 1.34 - 2.09; P<.0001). Absolute risk of death by 28-days increased with age and comorbidities. VOC has potential to spread faster with higher mortality than the pandemic to date.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Medical Research Council MR/V015737/1. TPP provided technical expertise and infrastructure within their data centre pro bono in the context of a national emergency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (reference 21863).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are stored in a secure platform and cannot be shared directly. Please see opensafely.org for access information.